PIK3CA and ovarian carcinoma: In the present study, we demonstrate for the first time that specific inhibition of the PI3K p110β isoform, but not p110α, resensitizes chemoresistant ovarian cancer cells, suggesting its potential ability for the therapeutic target on chemoresistant ovarian cancers.